At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 308 enrolled
Drug / intervention
placebo +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Late Phase 2 Study of OPC-12759 Ophthalmic Suspension
In Brief
A Phase 2 clinical trial evaluating placebo, 1% OPC-12759 ophthalmic suspension, and 1 other intervention for Dry Eye Syndromes. Completed, enrolled 308 participants across 6 sites.
Detailed Summary
The purpose of this study is to evaluate the dose-response of OPC-12759 suspension in dry eye patients
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Syndromes
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2007
First PostedMay 2007
Primary CompletionMar 2008
Study CompletionJun 2008
TodayJul 2026
First PostedMay 21, 2007
Enrollment StartMay 1, 2007
Primary CompletionMar 1, 2008
Study CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 19.1 years ago
Interventions
placebodrug
comparison of different dosages of drug
1% OPC-12759 ophthalmic suspensiondrug
comparison of different dosages of drug
2% OPC-12759 ophthalmic suspensiondrug
comparison of different dosages of drug